>> Platform Overview
GoldenPDCTM Platform:
Next-generation protein–drug conjugates
GoldenPDCTM is a next-generation site-specific conjugation platform designed to enable precise and efficient modification across virtually any position within a protein. Powered by ultra-fast click chemistry, it delivers >99% conjugation efficiency with exceptional homogeneity and batch-to-batch consistency. By eliminating the need for catalysts or enzymes, GoldenPDCTM simplifies the manufacturing workflow—supporting streamlined, scalable production and reliable performance for advanced protein conjugate development.
>> Platform Application
Empowering Next-Generation Immunotherapies
-
Antibody-Drug Conjugate (ADC) Development
GoldenPDC™ enables precise, site-specific conjugation for next-generation ADCs, supporting improved homogeneity, enhanced stability, optimized therapeutic windows, and predictable pharmacokinetic s for advanced oncology development.
-
Versatile Bioconjugate Engineering
The platform supports the development of diverse bioconjugates, including antibody–toxin and antibody–imaging constructs, delivering controlled modification with favorable biophysical properties and reduced non-specific interactions.
-
Therapeutic Window Optimization
Through rational site selection, GoldenPDC™ enhances biophysical performance, enabling higher effective dosing, improved safety margins, and expanded therapeutic windows for protein-based therapeutics.
-
Data-Driven Conjugation Design
Systematic site profiling generates high-quality datasets that support predictive modeling and AI-assisted optimization of conjugation positions for new targets and payloads.
>> Platform Advantages
Key Advantages of the GoldenPDC™ Platform
Site-Engineered Bioconjugates
GoldenPDC™ enables precise, fully controlled conjugation at defined positions across the protein, ensuring structural consistency and reproducibility.
Ultra-High Efficiency
Powered by rapid click chemistry, the platform achieves >99% conjugation efficiency, delivering exceptional homogeneity and batch-to-batch reliability.
Optimized Biophysical Profile
Site engineering supports antibody-like biophysical properties, minimizing hydrophobicity, self-interaction, and polyreactivity.
Catalyst-Free Workflow
GoldenPDC™ operates without the need for catalysts or enzymes, streamlining the manufacturing process and enabling efficient, scalable production.
>> Pipeline
Research & Development Pipeline
| Projects | Target | Target Selection | Screening | Lead Optimization | IND | Phase I | Phase II | Phase III |
|---|---|---|---|---|---|---|---|---|
| VLX-ADC1 | LIV-1 | |||||||
| VLX-ADC2 | UNDISCLOSED | |||||||
>> Contact Us
Get in Touch with Us
>> FAQs
Frequently Asked Questions
-
Q1: What makes GoldenPDC™ different from traditional conjugation technologies?
A: GoldenPDC™ allows access to every potential conjugation site within a protein, combined with rapid click-chemistry achieving >99% efficiency, resulting in highly homogeneous and well-defined conjugates. -
Q2: How does GoldenPDC™ improve drug development?
A: By enabling systematic site optimization, GoldenPDC™ produces conjugates with antibody-like biophysical properties, reducing development risks and improving pharmacokinetics, safety, and overall drug performance. -
Q3: What role does data and AI play in the GoldenPDC™ platform?
A: GoldenPDC™ generates structured datasets from systematic site profiling, supporting AI-driven prediction of optimal conjugation sites for new targets and payloads. -
Q4: How does GoldenPDC™ enhance the therapeutic window of drugs?
A: Through precise site selection, the platform minimizes unwanted properties such as hydrophobicity and self-interaction, enabling higher dosing with reduced toxicity. -
Q5: Does GoldenPDC™ simplify the manufacturing process?
A: Yes. The platform uses catalyst-free, enzyme-free chemistry, allowing a streamlined workflow of purification and conjugation without complex processing steps.
